Background
Phase III open-label RCT enrolling 432 patients with previously untreated CLL and coexisting conditions (CIRS score >6 or CrCl <70 mL/min), randomized 1:1 to a fixed-duration venetoclax-based regimen versus chemoimmunotherapy.
Interventions and follow up
Arm A: Obinutuzumab + venetoclax (12 cycles, fixed duration; venetoclax 5-week ramp-up to 400mg through cycle 12)
Arm B: Obinutuzumab + chlorambucil (12 cycles)
Primary endpoint: Investigator-assessed PFS
mFollow up: 28.1mo
Arm B: Obinutuzumab + chlorambucil (12 cycles)
Primary endpoint: Investigator-assessed PFS
mFollow up: 28.1mo
Results
24-mo PFS rate: 88.2% vs 64.1%, arm A vs B; HR 0.35, 95%CI 0.23–0.53; P<.001
Undetectable MRD (peripheral blood, end of treatment): 75.5% vs 35.2%, arm A vs B
Complete response: higher with venetoclax-obinutuzumab
OS: NR (no significant difference at this follow-up)
Undetectable MRD (peripheral blood, end of treatment): 75.5% vs 35.2%, arm A vs B
Complete response: higher with venetoclax-obinutuzumab
OS: NR (no significant difference at this follow-up)
Adverse events
Hematologic/cytopenias: Grade 3-4 neutropenia 52.8% vs 48.1%; thrombocytopenia 13.7% vs 15.0%, arm A vs B
Infections: Grade 3-4 infections 17.5% vs 15.0%; overall maximum grade 3-4 events 78.8% vs 76.6% (arm A vs B); tumor lysis syndrome managed with venetoclax ramp-up
Infections: Grade 3-4 infections 17.5% vs 15.0%; overall maximum grade 3-4 events 78.8% vs 76.6% (arm A vs B); tumor lysis syndrome managed with venetoclax ramp-up
Conclusions
Fixed-duration obinutuzumab-venetoclax produced significantly higher PFS and undetectable-MRD rates than obinutuzumab-chlorambucil in untreated CLL, supporting a time-limited chemotherapy-free option.
Key Limitations
Open-label design; chlorambucil-based comparator now outdated; follow-up at primary analysis relatively short for a fixed-duration regimen; tumor lysis risk requires structured ramp-up and monitoring.
Clinical Context
Led to FDA/EMA approval of fixed-duration venetoclax + obinutuzumab for previously untreated CLL. ESMO/iwCLL guidelines endorse this regimen as a preferred time-limited frontline option, alongside continuous BTK-inhibitor therapy; longer-term data confirm durable remissions after treatment cessation.